Rare but Severe Cardiovascular Complications of SARS-CoV-2 Vaccination: A Call for Awareness

The extensive use of severe acute respiratory syndrome coronavirus 2 vaccines has played a crucial role in controlling the coronavirus disease 2019 pandemic, underscoring the remarkable advantages and efficacy of novel vaccine technologies. However, rare but life-threatening cardiovascular complications such as myocarditis, pericarditis, and thrombosis have emerged, predominantly affecting young males after their second vaccine dose. These adverse events highlight the importance of continued pharmacovigilance and transparent communication about potential risks. Because the global epidemiologic context has shifted, now characterized by widespread natural, vaccine-induced, or hybrid immunity, it is important to re-evaluate the risk-benefit ratio of repeated vaccine administration in low-risk individuals. Data regarding severe acute respiratory syndrome coronavirus 2 vaccines complications are still largely based on the early phases of the pandemic (2020-2021), when population-level immunity was minimal and severe coronavirus disease 2019 outcomes more frequent. Today, such comparisons may no longer be appropriate. Updated real-world evidence is needed to better inform decision making and ensure that public health strategies remain aligned with the contemporary risk landscape.